SCHEMBL4906831

SCHEMBL4906831

NC(=O)N(CCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2ccnn2c1

nearest known ligand 0.61

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 17/20 0.61
DRD3 P35462 11/20 0.61
DRD4 P21917 7/20 0.61
HTR2A P28223 9/20 0.51
DRD1 P21728 3/20 0.51
HTR1A P08908 6/20 0.47
HTR7 P34969 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4914156 0.99 DRD2 (0.60) DRD2DRD3DRD4HTR2ADRD1
SCHEMBL4912035 0.97 DRD2 (0.59) DRD2DRD3DRD4HTR2ADRD1
SCHEMBL4915105 0.94 DRD2 (0.56) DRD2DRD3DRD4HTR2ADRD1
SCHEMBL4912048 0.87 DRD2 (0.61) DRD2DRD3DRD4HTR2ADRD1
SCHEMBL4916905 0.86 DRD2 (0.61) DRD2DRD3DRD4HTR2ADRD1
SCHEMBL4913327 0.84 DRD2 (0.62) DRD2DRD3DRD4HTR2ADRD1
Trifluoroacetic Acid SCHEMBL4907608 0.82 DRD2 (0.56) DRD2DRD3DRD4HTR2ADRD1
Trifluoroacetic Acid SCHEMBL4916862 0.81 DRD2 (0.55) DRD2DRD3DRD4HTR2ADRD1
SCHEMBL4913762 0.80 DRD2 (0.59) DRD2DRD3DRD4HTR2ADRD1
SCHEMBL4916604 0.80 DRD3 (0.47) DRD2DRD3DRD4HTR2ADRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778685-B1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SANOL ARZNEI SCHWARZ GMBH (DE) 2008-03-26 EP claimed
US-20080051409-A1 Indolizine Carboxamides and Aza and Diaza Derivatives Thereof SCHWARZ PHARMA AG (DE) 2008-02-28 US claimed
EP-1778685-A1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SCHWARZ PHARMA AG (DE) 2007-05-02 EP claimed
WO-2006015737-A1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SCHWARZ PHARMA AG (DE) 2006-02-16 WO claimed
EP-1778685-B1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SANOL ARZNEI SCHWARZ GMBH (DE) 2008-03-26 EP disclosed
US-20080051409-A1 Indolizine Carboxamides and Aza and Diaza Derivatives Thereof SCHWARZ PHARMA AG (DE) 2008-02-28 US disclosed
EP-1778685-A1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SCHWARZ PHARMA AG (DE) 2007-05-02 EP disclosed
WO-2006015737-A1 INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF SCHWARZ PHARMA AG (DE) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051409-A1 Indolizine Carboxamides and Aza and Diaza Derivatives Thereof GRIN2A, GRIN2C, GRIN1 DRD2 248/4885DRD3 474/4885DRD4 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.